What is ens@t-ht?
ens@t-ht is an EU-funded Horizon 2020 research and innovation project that will investigate specific types of hypertension and whether it is possible to define specific profiles based on systems biology "-omics" approaches and subsequently use these to define more personalised approaches to disease management
Disease context of ens@t-ht
They include a group of adrenal disorders resulting in increased production of hormones affecting blood pressure regulation: primary aldosteronism (PA), pheochromocytoma/functional paraganglioma (PPGL) and Cushing’s syndrome (CS). These diseases are associated with increased cardiovascular and metabolic risk and with diminished quality of life.
For ens@t-ht these diseases will form the major targets for our investigation into whether disease profiles can be defined via -omics and bioinformatics approaches and whether more personalised approaches to treatment and disease management are possible.
In more detail...
The project will develop and evaluate an omics-based stratified health promotion programme for patients with endocrine forms of hypertension.
We will define specific omics profiles for patients with primary aldosteronism, pheochromocytoma/functional paraganglioma and Cushing’s syndrome by integrating high throughput genetics, genomics and metabolomics data with phenome annotations through bioinformatics modelling.
Established profiles will be validated as stratification biomarkers and applied to the screening of referred hypertensive patients for both stratifying primary forms of hypertension for effective and cost efficient therapy as well as improving identification of endocrine causes for curative treatment and prevention of cardiovascular and metabolic complications.
The broader context of hypertension
Arterial hypertension affects about 45% of the general population and is responsible for 7.1 million deaths per year worldwide. Although a large therapeutic arsenal exists, blood pressure control is sub-optimal in up to two thirds of patients. Yet, even small increments in blood pressure are associated with increased cardiovascular risk, with 62% of cerebrovascular disease and 49% of ischemic heart disease being attributable to hypertension.
This year the ENSAT-HT consortium meeting will take place in Lyon, France from 16th to 17th May 2019.
Members from our Scientific Advisory Board will also be invited.